<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484040</url>
  </required_header>
  <id_info>
    <org_study_id>TwoArc trial</org_study_id>
    <nct_id>NCT02484040</nct_id>
  </id_info>
  <brief_title>Two-week Course Versus Conventionally Fractionated Chemoradiotherapy in Rectal Cancer</brief_title>
  <official_title>Two-Week COurse Versus Conventionally Fractionated Preoperative Chemoradiotherapy In Locally Advanced Rectal Cancer (TwoArc Trial): A Phase III Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jong Hoon Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators compare two-week course of chemoradiation (33 Gy in 10 fractions with oral
      capecitabine) and conventional chemoradiation (50.4 Gy in 28 fractions with 5-FU and
      leucovorin) in this randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.1 experimental arm Two-week course concurrent chemoradiotherapy

        -  Radiotherapy, 33 Gy/10 fractions for 2 weeks

           ↓↓↓↓↓ ↓↓↓↓↓ Radical surgery 6 weeks after completion of chemoradiotherapy
           D1----------------------D12

        -  Capecitabine 825 mg/m2, twice daily

      1.2 control arm

      Standard concurrent chemoradiotherapy (CRT)

        -  Radiotherapy, 50.4 Gy/28 fractions for 6 weeks

           ↓↓↓↓↓ ↓↓↓↓↓ ↓↓↓↓↓ ↓↓↓↓↓ ↓↓↓↓↓ ↓↓↓ Radical surgery
           D1--------------------------------------------------------------------------D38

        -  Bolus 5-FU, 400 mg/ m2 and leucovorin, 20 mg/ m2 during week 1 and 5

        -  Capecitabine, 825 mg/ m2, bid
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response from stage II-III to stage 0-I</measure>
    <time_frame>from clinical staging time to radical surgery date (about 3 months)</time_frame>
    <description>Downstaging rate was evaluated by comparing pre-clinical and post-CRT pathological stages, and downstaging was defined as ypStage 0-I (ypT0-2N0M0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (acute and chronic)</measure>
    <time_frame>from radiation start to 3 years after radical surgery</time_frame>
    <description>During the course of radiotherapy, patients were evaluated weekly to assess acute toxicity. Patients were also followed 2 and 4 weeks after completion of radiotherapy and until 3 years after curative surgery to assess toxicity. Toxicity are assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence and survival</measure>
    <time_frame>3-year recurrence-free survival and 3-year overall survival</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Response to Toxin</condition>
  <condition>Toxicity</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Two-week course arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm receive 33 Gy in 10 fractions of radiation for 2 weeks with oral capecitabine.
Two-week course of radiation, 33 Gy/10 fx and oral capecitabine, 825 mg/m2, bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventionally fractionated radiation of 50.4 Gy/28 fx and 5-FU, 500 mg/m2 and leucovorin, 20 mg/m2 for 5 days, monthly or Capecitabine, 825 mg/m2, bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Two-week course of radiation</intervention_name>
    <description>33 Gy in 10 fractions for 2 weeks</description>
    <arm_group_label>Two-week course arm</arm_group_label>
    <other_name>experimental arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Two-week course of radiation</intervention_name>
    <description>oral capecitabine, 825mg/m2, bid</description>
    <arm_group_label>Two-week course arm</arm_group_label>
    <other_name>experimental arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically confirmed adenocarcinoma;

          2. distal margin of the tumor located &lt; 10 cm from the anal verge;

          3. cT3-4N0-2 classification as determined by magnetic resonance imaging (MRI) and/or
             endorectal ultrasonography (EUS);

          4. no evidence of distant metastasis;

          5. Karnofsky performance score over 70;

          6. adequate bone marrow, liver, and renal function (leucocytes &gt;4000/mm3, hemoglobin &gt;10
             g/dL, platelets &gt;100,000/mm3; serum bilirubin &lt;1.5 mg/dL, serum transaminase &lt;2.5
             times the upper normal limit; serum creatinine &lt;1.5 mg/dL).

        Exclusion Criteria:

          1. Metastatic disease

          2. No complete resection of tumor (R2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Hoon Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's Hospital, The Catholic University of Kora</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong Hoon Lee, MD</last_name>
    <phone>+82-031-249-8440</phone>
    <email>koppul@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lee Jong Hoon</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Hoon Lee</last_name>
      <email>koppul@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Lee JH, Kim JG, Oh ST, Lee MA, Chun HG, Kim DY, Kim TH, Kim SY, Baek JY, Park JW, Oh JH, Park HC, Choi DH, Park YS, Kim HC, Chie EK, Jang HS. Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02). Radiother Oncol. 2014 Jan;110(1):150-4. doi: 10.1016/j.radonc.2013.11.013. Epub 2014 Jan 7.</citation>
    <PMID>24411228</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2015</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Jong Hoon Lee</investigator_full_name>
    <investigator_title>Mr.</investigator_title>
  </responsible_party>
  <keyword>tumor response</keyword>
  <keyword>toxicity</keyword>
  <keyword>recurrence</keyword>
  <keyword>chemoradiotherpy</keyword>
  <keyword>rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

